unstable angina undergoing PCI.

Nouveautés et perspectives dans le traitement anti-agrégant
PRAGUE-8 PRAGUE-8 ESC 2007.
PLATO Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. Held C et al. ACC 2010.
JPAD The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial. Efficacy of Low-Dose Aspirin Therapy for the Primary Prevention.
EXCELLENT The randomized comparison of 6-month vs 12-month duration of dual antiplatelet therapy after the implantation of drug eluting stent. Gwon H-C,
TAPAS Thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS) mortality and reinfarction at 1 year.
ON-TIME Intérêt de l’administration préhospitalière d’un bolus d’anti-GPIIb/IIIa à la phase aiguë d’un infarctus du myocarde traité par angioplastie coronaire.
FUTURA/OASIS-8 Low versus standard dose unfractionned heparin for percutaneous coronary intervention in acute coronary syndrome patients treated with fondaparinux.
ISAR-TEST 4 Intracoronary stenting and antirestenotic results : test efficacy of 3 limus-eluting stents Mehilli J et al.
FINESSE Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events ESC 2007 FINESSE.
CLEAR PLATELETS Variabilité génétiquement déterminée de l’effet du clopidogrel Influence du polymorphism du CYP2C19 sur les effets antiplaquettaires du.
GRACE The Global Registry of Acute Coronary Events Montalescot G et al.
COURAGE Nuclear Differential Improvement in Stress Myocardial Perfusion Ischemia following Percutaneous Coronary Intervention as compared with Optimal.
ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.
ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.
ELEVATE-TIMI 56 Increasing clopidogrel based on CYP2C19 genotype in patients with cardiovascular disease. Mega JL et al. AHA 2011.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
TITRATION DU CLOPIDOGREL Tailored Clopidogrel Loading Dose according to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis. Paganelli F et.
Apixaban versus warfarin in patients with atrial fibrillation
Revascularisation coronaire prophylactique avant chirurgie vasculaire
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
CARESS-AMI Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction ESC CARESS-AMI.
Registre MATRIX Long term safety of DES (drug eluting stents) in off-label use : results of the MATRIX registry. Dangas G.D et al. American College of.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
ISAR-REACT Anti-GPIIbIIIa (abciximab) en complément d’une dose de charge en clopidogrel avant angioplastie avec mise en place d’une endoprothèse coronaire.
EXPLORE-Xa Betrixaban Compared With Open‑Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation. Ezekowitz MD et al. ACC 2010.
Actualités sur les antiagrégants plaquettaires
TRA-CER Vorapaxar, a platelet thrombin receptor antagonist, in acute coronary syndromes. Mahaffey KW et al . AHA 2011.
ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.
un infarctus du myocarde récent.
TRIANA Tratamiento del infarto agudo de miocardio en ancianos Bueno H et al.
Platelet inhibition with cangrelor in patients undergoing PCI.
PRODIGY Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study Valgimigli M et al. ESC 2011.
ROCKET AF Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in Atrial.
Critère principal : décès CV, IDM ou AVC n = Médiane de suivi 33 mois
Mass-DAC Drug-Eluting and Bare Metal Stenting in Diabetes Mellitus : Results from the Mass-DAC Registry. Mauri L et al. AHA 2008.
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:
GRACIA 2 Angioplastie coronaire primaire (ATL I) ou ATL « facilitée » dans le traitement de l’infarctus du myocarde en voie de constitution. ESC, Vienne,
Étude TOTAL : thrombo-aspiration lors de l’angioplastie primaire (2)
PRAGUE 7 Primary angioplasty in patients from general hospital transported to cathlab units with/without emergency thrombolysis Widimski P et al.
EARLY-ACS Inhibition de la glycoprotéine IIb/IIIa dans le syndrome coronarien aigu sans sus-décalage de ST Newby K et al. ACC Anti-GPIIb/IIIa précoce.
Intravenous platelet blockade with cangrelor during PCI.
NORDISTEMI Norwegian study on district treatment of ST-elevation myocardial infarction Halvorsen S. et al.
TRITON-TIMI 38 Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infraction.
AVERROES Apixaban versus acetylsalicylic acid (ASA) to reduce the risk of stroke Connolly S et al. ESC 2010.
Revascularisation coronaire : ATL-endoprothèses ou chirurgie ?
AIDA STEMI The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Thiele H et al. AHA 2011.
ISAR-REACT 4 The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Kastrati A et al. AHA.
ICTUS Comparaison entre revascularisation coronaire précoce
Stents et anti-agrégants plaquettaires.
Prasugrel vs Clopidogrel for Patients managed with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography : a secondary,
CHARISMA Analyse post-hoc Complications hémorragiques de l’association clopidogrel + aspirine chez les patients avec maladie vasculaire stable ou avec.
ISAR-SAFE, ITALIC, DAPT Durée de la bithérapie AAP post ATL-stent actif Schulz-Schüpke S, et al. ISAR-SAFE, Gilard M, et al. ITALIC, Mauri L, et al. DAPT.
PRAGUE-14 Perioperative cardiovascular complications versus perioperative bleeding in patients with cardiovascular complications undergoing non- cardiac.
HEAT-PPCI Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI) : an open-label, single centre, randomised.
LODOCO Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease Nidorf M et al. AHA 2012.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS TIMI 51 ATLAS ACS 2 –TIMI 51 * Gibson CM.
CHARISMA Clopidogrel + aspirine contre aspirine seule pour la prévention des accidents athérothrombotiques. Bhatt DL et al. N Engl J Med 2006;354:
Aspirin in Patients Undergoing Non Cardiac Surgery POISE 2 Devereaux PJ et al. NEJM 2014;370:
POISE-2 Aspirin in patients undergoing noncardiac surgery ACC Devereaux P.J, et al. N Engl J Med 2014 ; 370 :
Recombinant Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery ATLANTIC.
JPPP Low-dose aspirin for primary prevention of cardiovascular events in elderly patients with multiple atherosclerotic risk factors. A randomized control.
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
ATLAS ACS 2 – TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome Gibson CM.
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
Platelet inhibition and patient outcomes
Strategies for Multivessel Revascularization in Patients with Diabetes
Host-ASSURE Adjunctive Cilostazol vs double dose clopidogrel after PCI with drug eluting stent Hyo-Soo K et al. ACC 2012.